

AGS 100

Rank	Article	Likert Score	Citations
1	Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO, Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):701-13.	3.69	2426
2	Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, Wilson MR, Kass MA, Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):714-20.	3.67	1780
3	Brandt JD, Beiser JA, Kass MA, Gordon MO, Ocular Hypertension Treatment Study Group. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology. 2001 Oct;108(10):1779-88.	3.66	471
4	The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000 Oct;130(4):429-40.	3.65	1951
5	Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL, Tube Versus Trabeculectomy Study Group. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) Study after five years of follow-up. Am J Ophthalmol. 2012 May;153(5):789-803.	3.60	476
6	The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998 Oct;126(4):498-505.	3.53	953
7	Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998 Oct;126(4):487-97.	3.43	1134
8	Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002 Oct;120(10):1268-79.	3.35	2033

9	Cairns JE. Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol. 1968 Oct;66(4):673-9.	3.35	726
10	Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: The Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003 Jan;121(1):48-56.	3.33	1325
11	Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N, Barton K, Rubin G, Buszewicz M, LiGHT Trial Study Group. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): A multicentre randomised controlled trial. Lancet. 2019 Apr 13;393(10180):1505-1516.	3.30	50
12	Azuara-Blanco A, Burr J, Ramsay C, Cooper D, Foster PJ, Friedman DS, Scotland G, Javanbakht M, Cochrane C, Norrie J, EAGLE Study Group. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): A randomised controlled trial. Lancet. 2016 Oct 1;388(10052):1389-1397.	3.27	120
13	Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977 Apr;95(4):601-4.	3.26	324
14	Grant WM, Burke JF Jr. Why do some people go blind from glaucoma? Ophthalmology. 1982 Sep;89(9):991-8.	3.24	274
15	Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC, Tube Versus Trabeculectomy Study Group. Postoperative complications in the Tube Versus Trabeculectomy (TVT) Study during five years of follow-up. Am J Ophthalmol. 2012 May;153(5):804-814.	3.20	356
16	Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP, CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001 Nov;108(11):1943-53.	3.19	805
17	Palmer SS. Mitomycin as adjunct chemotherapy with trabeculectomy. Ophthalmology. 1991 Mar;98(3):317-21.	3.19	541
18	Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z, EMGT Group. Predictors of long-term progression	3.16	813

in the Early Manifest Glaucoma Trial. *Ophthalmology*. 2007 Nov;114(11):1965-72.

19	Musch DC, Gillespie BW, Lichter PR, Niziol LM, Janz NK, CIGTS Study Investigators. Visual field progression in the Collaborative Initial Glaucoma Treatment Study: The impact of treatment and other baseline factors. <i>Ophthalmology</i> . 2009 Feb;116(2):200-7.	3.16	225
20	Christakis PG, Zhang D, Budenz DL, Barton K, Tsai JC, Ahmed IIK, ABC-AVB Study Groups. Five-year pooled data analysis of the Ahmed Baerveldt Comparison Study and the Ahmed Versus Baerveldt Study. <i>Am J Ophthalmol</i> . 2017 Apr;176:118-126.	3.16	44
21	Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. A pilot study. <i>Arch Ophthalmol</i> . 1979 Feb;97(2):319-22.	3.15	404
22	Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR, Ocular Hypertension Treatment Study Group. Delaying treatment of ocular hypertension: The Ocular Hypertension Treatment Study. <i>Arch Ophthalmol</i> . 2010 Mar;128(3):276-87.	3.13	88
23	Latina MA, Sibayan SA, Shin DH, Noecker RJ, Marcellino G. Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): A multicenter, pilot, clinical study. <i>Ophthalmology</i> . 1998 Nov;105(11):2082-8.	3.11	299
24	Drance S, Anderson DR, Schulzer M, Collaborative Normal-Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. <i>Am J Ophthalmol</i> . 2001 Jun;131(6):699-708.	3.10	504
25	Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D, Caprioli J, Advanced Glaucoma Intervention Study. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. <i>Ophthalmology</i> . 2004 Sep;111(9):1627-35.	3.10	467
26	Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt J, Singh K. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. <i>Arch Ophthalmol</i> . 1991 Aug;109(8):1090-5.	3.07	830
27	Becker B. Intraocular pressure response to topical corticosteroids. <i>Invest Ophthalmol</i> . 1965 Apr;4:198-205.	3.07	272

28	Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991 Jul 17;266(3):369-74.	3.06	1005
29	Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996 Jan;103(1):138-47.	3.05	475
30	Chen CW, Huang HT, Bair JS, Lee CC. Trabeculectomy with simultaneous topical application of mitomycin-C in refractory glaucoma. J Ocul Pharmacol. 1990 Fall;6(3):175-82.	3.05	407
31	He M, Jiang Y, Huang S, Chang DS, Munoz B, Aung T, Foster PJ, Friedman DS. Laser peripheral iridotomy for the prevention of angle closure: A single-centre, randomised controlled trial. Lancet. 2019 Apr 20;393(10181):1609-1618.	3.05	25
32	Schuman JS, Hee MR, Puliafito CA, Wong C, Pedut-Kloizman T, Lin CP, Hertzmark E, Izatt JA, Swanson EA, Fujimoto JG. Quantification of nerve fiber layer thickness in normal and glaucomatous eyes using optical coherence tomography. Arch Ophthalmol. 1995 May;113(5):586-96.	3.02	687
33	Campbell DG. Pigmentary dispersion and glaucoma. A new theory. Arch Ophthalmol. 1979 Sep;97(9):1667-72.	3.02	216
34	Heuer DK, Parrish RK, Gressel MG, Hodapp E, Palmberg PF, Anderson DR. 5-fluorouracil and glaucoma filtering surgery. II. A pilot study. Ophthalmology. 1984 Apr;91(4):384-94.	3.01	275
35	Bengtsson B, Olsson J, Heijl A, Rootzén H. A new generation of algorithms for computerized threshold perimetry, SITA. Acta Ophthalmol Scand. 1997 Aug;75(4):368-75.	3.00	273
36	Five-year follow-up of the Fluorouracil Filtering Surgery Study. The Fluorouracil Filtering Surgery Study Group. Am J Ophthalmol. 1996 Apr;121(4):349-66.	2.98	374
37	Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology.	2.97	408

1996 Jan;103(1):126-37.

38	Fluorouracil Filtering Surgery Study one-year follow-up. The Fluorouracil Filtering Surgery Study Group. Am J Ophthalmol. 1989 Dec 15;108(6):625-35.	2.95	369
39	Tielsch JM, Katz J, Singh K, Quigley HA, Gottsch JD, Javitt J, Sommer A. A population-based evaluation of glaucoma screening: The Baltimore Eye Survey. Am J Epidemiol. 1991;134(10):1102-1110.	2.95	334
40	Ocular Hypertension Treatment Study Group, European Glaucoma Prevention Study Group, Gordon MO, Torri V, Miglior S, Beiser JA, Floriani I, Miller JP, Gao F, Adamsons I, Poli D, D'Agostino RB, Kass MA. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology. 2007 Jan;114(1):10-9.	2.95	199
41	Sommer A, Katz J, Quigley HA, Miller NR, Robin AL, Richter RC, Witt KA. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol. 1991 Jan;109(1):77-83.	2.94	899
42	Mansberger SL, Gordon MO, Jampel H, Bhorade A, Brandt JD, Wilson B, Kass MA, Ocular Hypertension Treatment Study Group. Reduction in intraocular pressure after cataract extraction: The Ocular Hypertension Treatment Study. Ophthalmology. 2012;119(9):1826-1831.	2.94	147
43	The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Glaucoma Laser Trial Research Group. Am J Ophthalmol. 1995 Dec;120(6):718-31.	2.90	243
44	Budenz DL, Barton K, Gedde SJ, Feuer WJ, Schiffman J, Costa VP, Godfrey DG, Buys YM, Ahmed Baerveldt Comparison Study Group. Five-year treatment outcomes in the Ahmed Baerveldt Comparison Study. Ophthalmology. 2015;122(2):308-316.	2.89	106
45	Skuta GL, Beeson CC, Higginbotham EJ, Lichter PR, Musch DC, Bergstrom TJ, Klein TB, Falck FY Jr. Intraoperative mitomycin versus postoperative 5-fluorouracil in high-risk glaucoma filtering surgery. Ophthalmology. 1992 Mar;99(3):438-44.	2.87	415
46	Gedde SJ, Feuer WJ, Lim KS, Barton K, Goyal S, Ahmed IIK, Brandt JD, Primary Tube Versus Trabeculectomy Study Group. Treatment outcomes in the Primary Tube Versus Trabeculectomy Study after 3 years of follow-up. Ophthalmology. 2020;127(3):333-345.	2.87	11

47	Kitazawa Y, Kawase K, Matsushita H, Minobe M. Trabeculectomy with mitomycin. A comparative study with fluorouracil. Arch Ophthalmol. 1991 Dec;109(12):1693-8.	2.84	471
48	Bengtsson B, Leske MC, Hyman L, Heijl A, Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma progression in the Early Manifest Glaucoma Trial. Ophthalmology. 2007 Feb;114(2):205-9.	2.84	286
49	Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993 Sep;100(9):1297-304.	2.81	385
50	Hattenhauer MG, Johnson DH, Ing HH, Herman DC, Hodge DO, Yawn BP, Butterfield LC, Gray DT. The probability of blindness from open-angle glaucoma. Ophthalmology. 1998 Nov;105(11):2099-2104.	2.78	221
51	Ehlers N, Bramsen T, Sperling S. Applanation tonometry and central corneal thickness. Acta Ophthalmol (Copenh). 1975 Mar;53(1):34-43.	2.76	692
52	Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention Study. Ophthalmology. 2008 Jul;115(7):1123-1129.	2.76	297
53	Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005 Oct;140(4):598-606.	2.76	274
54	The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology. 1998;105(7):1146-1164.	2.75	176
55	Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J, Menage MJ. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology. 1992 Oct;99(10):1499-504.	2.72	748
56	Quigley HA, Miller NR, George T. Clinical evaluation of nerve fiber layer atrophy as an indicator of glaucomatous optic nerve damage. Arch Ophthalmol. 1980 Sep;98(9):1564-71.	2.72	242
57	Christakis PG, Kalenak JW, Tsai JC, Zurakowski D, Kammer JA, Harasymowycz PJ, Mura JJ, Cantor LB, Ahmed	2.72	61

IIK. The Ahmed Versus Baerveldt Study: Five-year treatment outcomes. *Ophthalmology*. 2016;123(10):2093-2102.

58	Leske MC, Wu SY, Hennis A, Honkanen R, Nemesure B, BEs Study Group. Risk factors for incident open-angle glaucoma: The Barbados Eye Studies. <i>Ophthalmology</i> . 2008 Jan;115(1):85-93.	2.71	452
59	De Moraes CG, Hood DC, Thenappan A, Girkin CA, Medeiros FA, Weinreb RN, Zangwill LM, Liebmann JM. 24-2 visual fields miss central defects shown on 10-2 tests in glaucoma suspects, ocular hypertensives, and early glaucoma. <i>Ophthalmology</i> . 2017 Oct;124(10):1449-1456.	2.70	48
60	Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. <i>Arch Ophthalmol</i> . 1981 Apr;99(4):635-49.	2.69	823
61	Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. <i>Am J Ophthalmol</i> . 1994;117(5):603-624.	2.69	630
62	Bindlish R, Condon GP, Schlosser JD, D'Antonio J, Lauer KB, Lehrer R. Efficacy and safety of mitomycin-C in primary trabeculectomy: Five-year follow-up. <i>Ophthalmology</i> . 2002 Jul;109(7):1336-41.	2.69	245
63	Risk factors for suprachoroidal hemorrhage after filtering surgery. The Fluorouracil Filtering Surgery Study Group. <i>Am J Ophthalmol</i> . 1992 May 15;113(5):501-7.	2.69	60
64	Quigley HA, Dunkelberger GR, Green WR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. <i>Am J Ophthalmol</i> . 1989 May 15;107(5):453-64.	2.68	857
65	Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I, European Glaucoma Prevention Study (EGPS) Group. Results of the European Glaucoma Prevention Study. <i>Ophthalmology</i> . 2005 Mar;112(3):366-75.	2.68	248
66	Quigley HA, Katz J, Derick RJ, Gilbert D, Sommer A. An evaluation of optic disc and nerve fiber layer examinations in monitoring progression of early glaucoma damage. <i>Ophthalmology</i> . 1992 Jan;99(1):19-28.	2.65	465
67	Medeiros FA, Zangwill LM, Bowd C, Vessani RM, Susanna R Jr, Weinreb RN. Evaluation of retinal nerve fiber layer, optic nerve head, and macular thickness measurements for glaucoma detection using optical	2.65	450

coherence tomography. Am J Ophthalmol. 2005 Jan;139(1):44-55.

68	Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996 May;80(5):389-93.	2.64	1829
69	Leske MC, Connell AM, Wu SY, Hyman LG, Schachat AP. Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol. 1995 Jul;113(7):918-24.	2.64	513
70	Greenfield DS, Siatkowski RM, Glaser JS, Schatz NJ, Parrish RK 2nd. The cupped disc. Who needs neuroimaging? Ophthalmology. 1998 Oct;105(10):1866-74.	2.64	79
71	Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995 Dec;102(12):1743-52.	2.63	493
72	Heijl A, Lindgren A, Lindgren G. Test-retest variability in glaucomatous visual fields. Am J Ophthalmol. 1989 Aug 15;108(2):130-5.	2.63	299
73	Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014 Nov;121(11):2081-90.	2.62	1547
74	Greenfield DS, Suñer IJ, Miller MP, Kangas TA, Palmberg PF, Flynn HW Jr. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol. 1996 Aug;114(8):943-9.	2.61	308
75	Khaw PT, Chiang M, Shah P, Sii F, Lockwood A, Khalili A. Enhanced Trabeculectomy: The Moorfields Safer Surgery System. Dev Ophthalmol. 2017;59:15-35.	2.61	14
76	Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, Nickerson RJ, Pool J, Colton TL, Ganley JP, Loewenstein JI, Dawber TR. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol. 1980 May-Jun;24(Suppl):335-610.	2.59	787
77	Anderson DR. Trabeculotomy compared to goniotomy for glaucoma in children. Ophthalmology. 1983 Jul;90(7):805-6	2.59	117

78	Hayreh SS. Blood supply of the optic nerve head and its role in optic atrophy, glaucoma, and oedema of the optic disc. <i>Br J Ophthalmol</i> . 1969 Nov;53(11):721-48.	2.58	479
79	Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. <i>Am J Ophthalmol</i> . 2003 May;135(5):688-703.	2.58	362
80	Malihi M, Moura Filho ER, Hodge DO, Sit AJ. Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota. <i>Ophthalmology</i> . 2014;121(1):134-141.	2.58	41
81	Samuelson TW, Katz LJ, Wells JM, Duh YJ, Giamporcaro JE, US iStent Study Group. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. <i>Ophthalmology</i> . 2011 Mar;118(3):459-67.	2.57	256
82	Lowe RF. Aetiology of the anatomical basis for primary angle-closure glaucoma. Biometrical comparisons between normal eyes and eyes with primary angle-closure glaucoma. <i>Br J Ophthalmol</i> . 1970 Mar;54(3):161-9.	2.55	365
83	Pederson JE, Anderson DR. The mode of progressive disc cupping in ocular hypertension and glaucoma. <i>Arch Ophthalmol</i> . 1980 Mar;98(3):490-5.	2.55	322
84	Quigley HA, Addicks EM, Green WR. Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. <i>Arch Ophthalmol</i> . 1982 Jan;100(1):135-46.	2.54	932
85	Van Herick W, Shaffer RN, Schwartz A. Estimation of width of angle of anterior chamber. Incidence and significance of the narrow angle. <i>Am J Ophthalmol</i> . 1969 Oct;68(4):626-9.	2.54	319
86	Samuelson TW, Chang DF, Marquis R, Flowers B, Lim KS, Ahmed IIK, Jampel HD, Aung T, Crandall AS, Singh K, HORIZON Investigators. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: The HORIZON Study. <i>Ophthalmology</i> . 2019 Jan;126(1):29-37.	2.54	31
87	Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study. Prevalence of open angle	2.53	497

glaucoma. Arch Ophthalmol. 1994 Jun;112(6):821-9.

88	Varma R, Ying-Lai M, Francis BA, Nguyen BB, Deneen J, Wilson MR, Azen SP, Los Angeles Latino Eye Study Group. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: The Los Angeles Latino Eye Study. Ophthalmology. 2004 Aug;111(8):1439-48.	2.53	296
89	Singh K, Mehta K, Shaikh NM, Tsai JC, Moster MR, Budenz DL, Greenfield DS, Chen PP, Cohen JS, Baerveldt GS, Shaikh S. Trabeculectomy with intraoperative mitomycin C versus 5-fluorouracil. Prospective randomized clinical trial. Ophthalmology. 2000;107(12):2305-2309.	2.53	141
90	Chen PP, Lin SC, Junk AK, Radhakrishnan S, Singh K, Chen TC. The effect of phacoemulsification on intraocular pressure in glaucoma patients: A report by the American Academy of Ophthalmology. Ophthalmology. 2015;122(7):1294-1307.	2.53	95
91	Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000 Apr;9(2):134-42.	2.52	643
92	Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability. Ophthalmology. 1994 Aug;101(8):1445-55.	2.51	380
93	Armaly MF, Krueger DE, Maunder L, Becker B, Hetherington J Jr, Kolker AE, Levene RZ, Maumenee AE, Pollack IP, Shaffer RN. Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects. Arch Ophthalmol. 1980 Dec;98(12):2163-71.	2.51	280
94	Argus WA. Ocular hypertension and central corneal thickness. Ophthalmology. 1995;102(12):1810-1812.	2.51	247
95	Samuelson TW, Sarkisian SR Jr, Lubeck DM, Stiles MC, Duh YJ, Romo EA, Giamporcaro JE, Hornbeak DM, Katz LJ, iStent inject Study Group. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: Two-year results. Ophthalmology. 2019 Jun;126(6):811-821.	2.51	22
96	Musch DC, Gillespie BW, Palmberg PF, Spaeth G, Niziol LM, Lichter PR. Visual field improvement in the Collaborative Initial Glaucoma Treatment Study. Am J Ophthalmol. 2014 Jul;158(1):96-104.	2.50	23

97	Liu JH, Zhang X, Kripke DF, Weinreb RN. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1586-90.	2.49	306
98	Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, Novack GD, Kopczynski CC, ROCKET-1 and ROCKET-2 Study Groups. Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018 Feb;186:116-127.	2.48	50
99	Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR, Sunden SL, Nishimura D, Clark AF, Nystuen A, Nichols BE, Mackey DA, Ritch R, Kalenak JW, Craven ER, Sheffield VC. Identification of a gene that causes primary open angle glaucoma. Science. 1997 Jan 31;275(5300):668-70.	2.47	1150
100	Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology. 1994 Oct;101(10):1651-6.	2.47	291